Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma

Condition:   Severe IgE-mediated Asthma
Interventions:   Drug: Omalizumab;   Drug: Budesonide;   Drug: Formoterol
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting – verified July 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days